Combinatorial synthesis and biomarker development

• US 10,458,995 B2
• Filed: 03/21/2017
• Issued: 10/29/2019
• Est. Priority Date: 03/25/2016
• Status: Active Grant

• Current Assignee: Muralidhar Reddy Moola
• Original Assignee: Muralidhar Reddy Moola
• Inventors: Moola, Muralidhar Reddy
• Primary Examiner(s): Weidner, Adam
• Application Number:
  US16/088,033
• Publication Number:
  US 20190113521A1
• Time in Patent Office: 952 Days
• Field of Search: None
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: B01J 19/0046 Sequential or parallel reactions, e.g. for the synthesis of polypeptides or polynucleotides; Apparatus and devices for combinatorial chemistry or for making molecular arrays synthesis methods per se C40B50/00
• CPC Class Codes: B01J 2219/00648 by the use of solid beads
• CPC Class Codes: B01J 2219/00725 Peptides
• CPC Class Codes: C07K 1/047 Simultaneous synthesis of different peptide species; Peptide libraries
• CPC Class Codes: C07K 7/06 having 5 to 11 amino acids
• CPC Class Codes: C40B 30/04 by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
• CPC Class Codes: G01N 2500/04 Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
• CPC Class Codes: G01N 2800/2814 Dementia; Cognitive disorders
• CPC Class Codes: G01N 2800/2821 Alzheimer
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 2800/60 Complex ways of combining multiple protein biomarkers for diagnosis
• CPC Class Codes: G01N 33/6854 Immunoglobulins
• CPC Class Codes: G01N 33/6896 Neurological disorders, e.g. Alzheimer's disease

Abstract

Provided herein are methods, kits, and compositions for use in the diagnosis and treatment of diseases. Peptoids recognized by Alzheimers disease specific antibodies are identified.

Claims

1. A peptoid or pharmaceutically acceptable salt thereof comprising a formula:

2. The peptoid or pharmaceutically acceptable salt thereof of claim 1, comprising a structure

3. The peptoid or pharmaceutically acceptable salt thereof of claim 1, comprising a structure

4. The peptoid or pharmaceutically acceptable salt thereof of claim 1, comprising a structure

5. The peptoid or pharmaceutically acceptable salt thereof of claim 1, comprising a structure

6. The peptoid or pharmaceutically acceptable salt thereof of claim 1, comprising a structure

7. The peptoid or pharmaceutically acceptable salt thereof of claim 1, comprising a structure

8. The peptoid or pharmaceutically acceptable salt thereof of claim 1, comprising a structure

9. The peptoid or pharmaceutically acceptable salt thereof of claim 1, comprising a structure

10. The peptoid or pharmaceutically acceptable salt thereof of claim 1, comprising a structure

11. A method comprising;

a. contacting a sample with one or more peptoid or pharmaceutically acceptable salt thereof, wherein said one or more peptoid or pharmaceutically acceptable salt thereof comprises a formula;

12. A method comprising:

a. contacting a sample with a non-random peptoid library, wherein said non-random peptoid library comprises one or more peptoid or pharmaceutically acceptable salt thereof having an affinity to an antibody, wherein said antibody comprises an IgA or a fragment thereof, or an IgM or a fragment thereof wherein said one or more peptoid or pharmaceutically acceptable salt thereof comprises a formula;

13. A method of screening for a biomarker comprising:

a. contacting a control sample with a support having one or more peptoid or pharmaceutically acceptable salt thereof associated with said support, wherein said one or more peptoid or pharmaceutically acceptable salt thereof comprises a formula;

14. A method comprising:

a. contacting one or more peptoid or pharmaceutically acceptable salt thereof with a support having at least one biomarker associated with said support, wherein said one or more peptoid or pharmaceutically acceptable salt thereof comprises a formula;